RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

AstraZeneca

Status

Completed

Conditions

Non-small Cell Lung Cancer

Treatments

Drug: Durvalumab

Study type

Observational

Funder types

Industry

Identifiers

NCT05933044

D4191R00028

Details and patient eligibility

About

In the RELEVANCE study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage III NSCLC population in Canada across several Canadian cancer centres. Subsequent analyses will examine treatment patterns and clinical outcomes, including overall survival, for these patients, stratified by durvalumab regimen or non-durvalumab regimen during the time of the PACIFIC Patient Support Program.

Enrollment

662 patients

Sex

All

Ages

18 to 130 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female aged 18 years or older
Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent (stage III) disease between November 1, 2017 and December 31, 2019 at the centre (Note: durvalumab uptake rate requires a secondary index date, such as initiation of CRT before availability of durvalumab in May 2018)

Exclusion criteria

Patients treated with durvalumab in clinical studies prior to the start date
Clinical trial patients where treatments received are blinded in the patient medical records